Molecule intelOpportunity: ModerateEssential

Bupivacaine

42 brands · 16 companies · product forms

ATC: N01BB01

Opportunity snapshot

Launch attractiveness
46
Market saturation
45
Price room
100
Regulatory risk
0
42
brands
16
companies
Rs 339.66
median price
38
price points
14.77x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 14%

Price room

Across observed sources and strengths
CheapestRs 41.94
MedianRs 339.66
Most expensiveRs 619.6
Spread14.77×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 14.77x across 38 trusted points (Rs 41.94-619.6). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Bupivacaine — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(55) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

16 canonical companies and 42 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 14.77x across 38 trusted points (Rs 41.94-619.6). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.